Fig. 5

Nintedanib inhibits the differentiation of fibrocytes induced by growth factors. HMNC were cultured on fibronectin-coated dishes in medium containing low amounts of FBS. Recombinant growth factors such as (a) FGF-2 (30 ng/ml), (b) PDGF-BB (100 ng/ml), and (c) VEGF-A (100 ng/ml) and growth factor inhibitors (BGJ398 for FGFR, imatinib for PDGFR, SU5416 for VEGFR, and nintedanib) were administrated every 48 h. On day 6, attached cells were stained with the Diff-quick stain, and counted in 5 fields at 100× magnification. Data were analyzed using the Kruskal-Wallis H test and are displayed as median and interquartile range of three separate experiments (n = 15 in each group). In all graphs: *P < 0.05 versus the group treated with growth factors (FGF2 or PDGF-BB or VEGF-A) alone. HPF; high-power fields